CANA/Met in Non-diabetic Women With PCOS
Model scores of the 29,894 trials active now.
Model score 10% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (851 trials).
Finished trial that started in 2015 or later: the model never saw it during training.
How it ended
Completed on 2022-03-08, after 2021-04-07 start.
The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.
Termination over time, as the model saw it at the start
Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-03-08. The rest of the way to 100% is still running.
From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.
What moved the score
-
Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
-
Wording of the registration (title, summary, criteria) (lowers risk) · Wording
Phrases that raised it: kidneydiabeticsyndromeweightmetformin
Phrases that lowered it: ovarianeffectwomentumorsresistance -
Accepts healthy volunteers: No (raises risk) · Who can join
-
Disease area, cancer: Yes (raises risk) · Disease area
-
Phase: 1/2 (raises risk) · Design
-
Has a data monitoring committee: not given (lowers risk) · Design
-
Responsible party: principal investigator (lowers risk) · Design
-
Design: parallel (raises risk) · Design
-
Drug's FAERS reports with a death: 7.7% (lowers risk) · Drug's FDA history
-
Minimum age: 18 (raises risk) · Who can join
-
Sponsor type: academic or other (raises risk) · Sponsor's track record
-
Drug's FAERS reports marked serious: 66.4% (lowers risk) · Drug's FDA history
-
Drug's FAERS reports before start: 359905 (lowers risk) · Drug's FDA history
-
Primary purpose: treatment (raises risk) · Design
-
Blinding: none (raises risk) · Design
-
Sponsor's past trials: 11 (raises risk) · Sponsor's track record
-
Number of arms: 2 (raises risk) · Design
-
Maximum age: 45 (lowers risk) · Who can join
Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.
The trial
Design
- Phase
- 1/2 (typical: 2)
- Number of arms
- 2
- Allocation
- randomized
- Design
- parallel
- Primary purpose
- treatment
- Blinding
- none
- Has a data monitoring committee
- not given (typical: 56% yes)
- Responsible party
- principal investigator (typical: sponsor)
- Collaborators
- 0
- Keywords listed
- 0 (typical: 1)
Who can join
- Minimum age
- 18
- Maximum age
- 45 (typical: 71)
- Sex
- female (typical: all)
- Accepts healthy volunteers
- No (typical: 9% yes)
Sponsor's track record
- Sponsor type
- academic or other
- Sponsor's past trials
- 11 (typical: 32)
- Sponsor's past termination rate
- 0% (typical: 9.9%)
- Trials the sponsor started in the prior 2 years
- 14 (typical: 19)
Drug's FDA history
- Drugs with FDA adverse-event history
- 2 (typical: 1)
- Drug has FAERS history
- Yes (typical: 64% yes)
- Drug's FAERS reports before start
- 359905 (typical: 2148)
- Drug's FAERS reports in the prior 12 months
- 35961 (typical: 412.5)
- Drug's FAERS reports marked serious
- 66.4% (typical: 85.6%)
- Drug's FAERS reports with a death
- 7.7% (typical: 15.9%)
Disease area and drugs
- Disease areas
- cancer, urogenital, endocrine
- Drugs matched to FDA substances
- canagliflozin, metformin
Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.
Similar finished trials
- Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity NCT06140108 · started 2023 · scored riskier than 16% of active trials completed
- Chiglitazar/Metformin in Non-obese Women With PCOS NCT06125587 · started 2023 · scored riskier than 11% of active trials completed
- Dapagliflozin Efficacy and Action in PCOS NCT04213677 · started 2020 · scored riskier than 11% of active trials completed
- Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome NCT06405178 · started 2026 · scored riskier than 14% of active trials completed
- Metformin Improves Clinical Pregnancy Rate in Polycystic Ovarian Syndrome Patients NCT02562664 · started 2014 · scored riskier than 16% of active trials completed
Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.